This After Market Study is Seeing if Dupilumab Plus Usual Standard of Care (SOC) is Better Than Usual Care Alone for Adult Participants After a Severe Chronic Obstructive Pulmonary Disease (COPD) Flare-Up Requiring Hospitalization

This study is researching a drug called dupilumab, referred to as "study drug". The study is focused on people diagnosed with COPD to determine if the study drug, in addition to standard of care treatment for COPD, might reduce the reoccurrence of a COPD exacerbation (a "flare-up") happening within the study treatment duration (around 90 days). The study is looking at another research question: • What side effects may happen from taking the study drug

NCT Number	NCT07587658
Lead Sponsor	Regeneron Pharmaceuticals Collaborators: Sanofi
Conditions	Chronic Obstructive Pulmonary Disease (COPD)
Enrollment	754 participants
Start Date	2026-06-30
Primary Completion	2028-07-30 (estimated)
Study Completion	2028-07-30 (estimated)
Updated on ClinicalTrials.gov	2026-05-14